Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6774036 | 1.00 | OPRD1 (0.53) | OPRD1OPRM1MTNR1AMTNR1BLMNA | |
| SCHEMBL7269968 | 0.87 | OPRD1 (0.56) | OPRD1OPRM1MTNR1AMTNR1BLMNA | |
| SCHEMBL7269978 | 0.87 | OPRD1 (0.56) | OPRD1OPRM1MTNR1AMTNR1BLMNA | |
| SCHEMBL7262597 | 0.85 | OPRD1 (0.54) | OPRD1OPRM1MTNR1AMTNR1BLMNA | |
| SCHEMBL7270787 | 0.85 | OPRD1 (0.54) | OPRD1OPRM1MTNR1AMTNR1BLMNA | |
| SCHEMBL7262605 | 0.81 | OPRD1 (0.55) | OPRD1OPRM1 | |
| SCHEMBL1868573 | 0.80 | HPGD (0.71) | OPRD1OPRM1LMNAHPGDTSHR | |
| SCHEMBL6779935 | 0.80 | OPRD1 (0.53) | OPRD1OPRM1LMNAHPGDTSHR | |
| SCHEMBL6779941 | 0.80 | OPRD1 (0.53) | OPRD1OPRM1LMNAHPGDTSHR | |
| SCHEMBL1987981 | 0.79 | HPGD (0.65) | OPRD1OPRM1MTNR1BLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790854-B2 | TREATMENT OF DEPRESSION, EPILEPSY AND PARKINSON'S ISEASE, ANALGESICS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20030176693-A1 | Diphenylalkylamine derivatives useful as opioid receptor agonists | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1277737-A1 | DIPHENYLALKYLAMINE DERIVATIVES USEFUL AS OPIOID DELTA RECEPTOR AGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176693-A1 | Diphenylalkylamine derivatives useful as opioid receptor agonists | OPRM1, OPRK1, OPRL1 | OPRD1 4/4885OPRM1 1/4885MTNR1A 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.